Pulling SEC filings + quote and writing the call…
BBIO
BridgeBio Pharma, Inc.
Next earnings Aug 3, 2026 · consensus $-0.56 EPS, $229M rev
Last earnings -0.9% on 2026-05-07
$66.27
▼ -1.66%$66.27▲ +61.08%
over 1Y
L $40.00EODHDH $79.91
Earnings Dividend Split Congress buy Congress sellFilings colored by tone · hover for detail
Today-1.7%
1W-1.9%
1M+0.4%
3M-5.4%
YTD-15.3%
1Y+61.1%
Hold
Conviction
Horizon
Long (>12mo)
Street · 29 analysts
Buy
A blistering drug-launch ramp (+126% revenue) tempered by deep losses, negative equity and $2B of debt — high-risk growth.
BridgeBio is a commercial-stage rare-disease biopharma in the early innings of a major product launch. FY2025 revenue more than doubled — up 126.3% to $502M — the signature of a successful new-drug ramp (its ATTR-cardiomyopathy franchise). That top-line trajectory is the entire bull case: if the launch keeps compounding at anything close to this pace, the company grows into a valuation that currently sits at 25.6x sales.
Sources: SEC EDGAR (CIK 0001743881, latest 10-Q filed 2026-05-07) · EODHD · analysis by claude-code · as of 6/21/2026, 8:46:04 PM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.